Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details)

v3.5.0.2
Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) - Contingent Consideration [Member]
$ in Thousands
9 Months Ended
Sep. 30, 2016
USD ($)
Asuragen [Member]  
Beginning Balance $ 4,628
Payments (450)
Accretion 243
Adjustments to Fair Value (1,174)
Ending Balance 3,247
RedPath [Member]  
Beginning Balance 13,921
Payments
Accretion 732
Adjustments to Fair Value
Ending Balance 14,653
Beginning Balance 18,549
Payments (450)
Accretion 975
Adjustments to Fair Value (1,174)
Ending Balance $ 17,900